Skip to content

News Releases

Date Title and Summary Additional Formats
Toggle Summary Mirati Therapeutics Reports First Quarter 2019 Financial Results
SAN DIEGO , April 29, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the first quarter ended March 31, 2019 . First Quarter Highlights January 7 th , we announced a clinical collaboration with
View HTML
Toggle Summary Mirati Therapeutics To Present At The H.C. Wainwright & Co. Global Life Sciences Conference
SAN DIEGO , April 1, 2019 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the H.C. Wainwright & Co. Global Life Sciences Conference in London, England on Monday, April 8 th at 11:30am BST / 6:30am ET / 3:30am PT . Christopher C.
View HTML
Toggle Summary Mirati Therapeutics To Present At Upcoming Healthcare Conferences
SAN DIEGO , March 5, 2019 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at two upcoming healthcare conferences. Cowen 39 th Annual Healthcare Conference in Boston on Tuesday, March 12 th at 11:20 a.m. ET / 8:20 a.m. PT .
View HTML
Toggle Summary Mirati Therapeutics Reports Fourth Quarter Financial Results
SAN DIEGO , Feb. 28, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the fourth quarter and full-year ended December 31, 2018 . "Mirati made great progress in 2018 with significant advances in our
View HTML
Toggle Summary Mirati Therapeutics Announces The Appointment Of Faheem Hasnain As Chairman Of The Board Of Directors
SAN DIEGO , Feb. 19, 2019 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the appointment of Faheem Hasnain as Chairman of the Board, effective February 15, 2019 . Dr. Rodney Lappe Ph.D.
View HTML
Toggle Summary Mirati Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum & Oncology Day
SAN DIEGO , Feb. 7, 2019 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in the Guggenheim Healthcare Talks Idea Forum & Oncology Day in New York on Thursday, February 14 th at 11:00 a.m. ET / 8:00 a.m. PT .
View HTML
Toggle Summary Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
SAN DIEGO , Jan. 22, 2019 /PRNewswire/ --  Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the closing of its previously announced underwritten public offering of 1,854,838 shares of its common stock at a public offering price of $62 .00 per share.
View HTML
Toggle Summary Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
SAN DIEGO , Jan. 16, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 1,612,903 shares of its common stock at a price to the public of $62.00 per share. The aggregate gross proceeds from this offering are expected to be
View HTML
Toggle Summary Mirati Therapeutics Announces Proposed Public Offering Of Common Stock
SAN DIEGO , Jan. 16, 2019 /PRNewswire/ --  Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced that it intends to offer and sell, subject to market and other conditions, $75.0 million of shares of its common stock in an underwritten public offering.
View HTML
Toggle Summary Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor
SAN DIEGO , Jan. 15, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, announced today that it has dosed the first patient in a Phase 1/2 clinical trial of MRTX849, an investigational KRAS G12C inhibitor for patients with advanced solid
View HTML